Pharmaceutical Compositions For The Treatment Of Capillary Arteriopathy

Abstract

The present invention relates to the use of ergot derivatives or ergolines, and in particular of lisuride and terguride for the prophylaxis and treatment of constrictive capillary arteriopathy. Constrictive capillary arteriopathy refers to the diseases pulmonary arterial hypertension, endogenously induced or exogenously induced glomeruloscleroses as well as secondary Raynaud's syndrome.

1 . Lisuride or Terguride 
     as well as
 salts, enantiomers, mixtures of enantiomers, diastereomers, mixtures of diastereomers, hydrates, solvates and racemates thereof for the treatment and prophylaxis of pulmonary arterial hypertension, endogenously induced or exogenously induced glomeruloscleroses, or secondary Raynaud's syndrome. 
 
   
   
       2 . (canceled) 
   
   
       3 . Use of lisuride or terguride as well as salts, enantiomers, mixtures of enantiomers, diastereomers, mixtures of diastereomers, hydrates, solvates and reacemates thereof for the preparation of a pharmaceutical preparation for the treatment and prophylaxis of pulmonary arterial hypertension, endogenously induced or exogenously induced glomeruloscleroses as well as secondary Raynaud's syndrome. 
   
   
       4 . Pharmaceutical compositions, comprising at least one of the compounds lisuride or terguride as well as salts, enantiomers, mixtures of enantiomers, diastereomers, mixtures of diastereomers, hydrates, solvates and reacemates thereof in a concentration of active substances of 0.1 to 10 mg per single dose together with pharmacologically compatible carriers, auxiliary substances solvents, or combinations thereof. 
   
   
       5 . The pharmaceutical composition of  claim 4 , wherein the pharmaceutical composition is suitable for oral, sublingual, parenteral, cutaneous, buccal, percutaneous, subcutaneous, inhalative or nasal administration. 
   
   
       6 . The pharmaceutical composition of  claim 4  provided as tablets, layered tablets, capsules, retard-oral medicines, transdermal systems, suppositories, micro-formulations, nano-formulations, liposomal formulations, drops, nose drops, nose sprays, aerosols, ampoules, solutions, emulsions, dispersions, powders, inhalation powders, micro-crystalline formulations, inhalation sprays, transdermal systems or subcutaneous formulations. 
   
   
       7 . The pharmaceutical composition of  claim 4  provided as tablets, layered tablets, capsules, retard-oral medicines, transdermal systems, suppositories, micro-formulations, nano-formulations, liposomal formulations, drops, nose drops, nose sprays, aerosols, ampoules, solutions, emulsions, dispersions, powders, inhalation powders, micro-crystalline formulations, inhalation sprays, transdermal systems or subcutaneous formulations.